Tellabs, Inc. (NASDAQ:TLAB) will unveil its latest earnings on Tuesday, January 31, 2012. The average estimate of analysts is for net loss of 2 cents per share, a swing from net income of 2 cents in the year earlier quarter. The average estimate is the same as three months ago. Between one and three months ago, the average estimate was unchanged. It also has not changed during the last month. For the year, analysts are projecting a loss of 11 cents per share, a swing from profit of 47 cents last year.

The company has fallen in line with estimates the last two quarters. In the third quarter, it reported net loss of one cent per share and two quarters ago booked a loss of 3 cents. Analysts are projecting a decline of 23% in revenue from the year-earlier quarter to $316 million.

Competitors to Watch: ADTRAN, Inc. (NASDAQ:ADTN), Ciena Corporation (NASDAQ:CIEN), Sycamore Networks, Inc. (NASDAQ:SCMR), Ditech Networks Inc. (NASDAQ:DITC), Calix, Inc. (NYSE:CALX), Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC), Juniper Networks, Inc. (NYSE:JNPR), Cisco Systems, Inc. (NASDAQ:CSCO), Sonus Networks, Inc. (NASDAQ:SONS), and Alcatel-Lucent (NYSE:ALU).

Biogen Idec, Inc. (NASDAQ:BIIB) will unveil its latest earnings on Tuesday, January 31, 2012. The average estimate of analysts is for net income of $1.47 per share, a rise of 4.3% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from $1.55. Between one and three months ago, the average estimate moved down. It has been unchanged at $1.47 during the last month. Analysts are projecting profit to rise by 15.9% versus last year to $5.83.

Last quarter, the company came in at profit of $1.57 per share against a mean estimate of net income of $1.51 per share, beating estimates after missing them in the previous quarter. In the second quarter, it missed forecasts by 4 cents. On average, analysts predict $1.29 billion in revenue this quarter, a rise of 5.7% from the year ago quarter. Analysts are forecasting total revenue of $5.01 billion for the year, a rise of 6.1% from last year’s revenue of $4.72 billion.

Competitors to Watch: Elan Corp., plc (NYSE:ELN), Amgen, Inc. (NASDAQ:AMGN), Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA), Abbott Laboratories (NYSE:ABT), Merck & Co., Inc. (NYSE:MRK), Genzyme Corporation (NASDAQ:GENZ), Pfizer Inc. (NYSE:PFE), GlaxoSmithKline plc (NYSE:GSK), and Bristol Myers Squibb Co. (NYSE:BMY).

Get Your FREE Special Report: 4 Things You Must Know About the US Economy Now!